223472-23-9

Upstream product

• 4652-65-7 (S)-2-Benzyloxycarbonylamino-pentanedioic acid 5-methyl ester 
• 39538-31-3 methyl (4S)-4-{[(benzyloxy)carbonyl]amino}-5-[(2,5-dioxo-1-pyrrolidinyl)oxy]-5-oxopentanoate 
• 119109-58-9 4-(S)-[4-(N-benzyloxycarbonylamino)-5-hydroxy]pentanoic acid methyl ester 
• 3188-13-4 ethyl chloromethyl ether 

Downstream Products

• 861819-88-7 methyl (4S)-5-ethoxymethoxy-4-[(4-methylbenzoyl)amino]pentanoate 
• 861819-89-8 (4S)-5-ethoxymethoxy-4-[(4-methylbenzoyl)amino]pentanoic acid 
• 911050-88-9 methyl (2S,4S)-4-[(benzyloxy)carbonyl]amino-5-ethoxymethoxy-2-methylpentanoate 
• 911050-52-7 (2S,4S)-5-ethoxymethoxy-2-ethyl-4-[(4-phenoxybenzoyl)amino]pentanoic acid 
• 911050-51-6 methyl (2S,4S)-5-ethoxymethoxy-2-ethyl-4-[(4-phenoxybenzoyl)amino]pentanoate 
• 911050-90-3 methyl (2S,4S)-5-ethoxymethoxy-2-methyl-4-[(4-phenoxybenzoyl)amino]pentanoate 
• 223472-25-1 (2S,4S)-5-ethoxymethoxy-2-methyl-4-[(4-phenoxybenzoyl)amino]pentanoic acid 
• 223472-21-7 methyl (4S)-5-ethoxymethoxy-4-[(4-phenoxybenzoyl)amino]pentanoate 

Relevant academic research and scientific papers

Design and synthesis of an orally active matrix metalloproteinase inhibitor

A series of 4-(4-phenoxy)benzoylamino-4-methoxymethyloxymethyl butyric acid hydroxamates, which were derived from l-glutamic acid, were synthesized and evaluated as matrix metalloproteinase inhibitors. Most of the compounds listed in Tables 1-3 exhibited

Novel matrix metalloproteinase inhibitors: Generation of lead compounds by the in silico fragment-based approach

Generation of structurally new matrix metalloproteinase inhibitors was successfully carried out using an in silico technique. In order to identify the small fragment interacting with residues in the S1′ pocket of MMP-1 through hydrogen bonds, we performed in silico screening using the LUDI program. As a result, acetyl-l-alanyl-(N-methyl)amide (Ac-l-Ala-NHMe) was selected to link with another fragment, hydroxamic acid that interacted with catalytic zinc. By this approach, the l-glutamic acid derivative 2b was discovered to be a new type of matrix metalloproteinase inhibitor. Further transformation to reduce its peptidic nature and improve activity yielded nonpeptidic lead compounds as inhibitors of MMP-1, -2, -3, and -9.

4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient

Aminobutylic acid derivatives of the formula (I) wherein the symbols are as defined in specification; and non-toxic salts thereof. Because of inhibiting matrix metalloproteinase, the compounds of the formula (I) are useful for prevention and/or treatment

4-AMINOBUTANOIC ACID DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT

Aminobutylic acid derivatives of the formula (I) : wherein the symbols are as defined in specification; and non-toxic salts thereof. Because of inhibiting matrix metalloproteinase, the compounds of the formula (I) are useful for prevention and/or treatmen